SCHEMBL792147

SCHEMBL792147

O=S(=O)(NCCCCN1CCN(c2cccc3c2OCCO3)CC1)c1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.61
HTR6 P50406 5/20 0.61
HTR1A P08908 10/20 0.57
DRD2 P14416 6/20 0.57
HTR2A P28223 4/20 0.57
NPC1 O15118 1/20 0.53
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
THPO P40225 1/20 0.53
MTOR P42345 1/20 0.53
RAB9A P51151 1/20 0.53
HIF1A Q16665 1/20 0.53
HSD17B10 Q99714 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL791710 0.97 HTR7 (0.57) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL792327 0.86 HTR1A (0.53) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL791587 0.85 HTR7 (0.58) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL793365 0.84 HTR1A (0.66) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL793242 0.83 HTR1A (0.54) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL793277 0.82 HTR1A (0.59) HTR7HTR1ADRD2HTR2A
SCHEMBL791832 0.82 DRD2 (0.60) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL792926 0.82 HTR7 (0.54) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL791558 0.81 HTR7 (0.68) HTR7HTR6HTR1ADRD2HTR2A
SCHEMBL798862 0.81 HTR1A (0.51) HTR7HTR6HTR1ADRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP claimed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US claimed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO claimed
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2014-11-13 US disclosed
US-8822517-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z O.O. (PL) 2014-09-02 US disclosed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP disclosed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US disclosed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS HTR7 1419/4885HTR6 1131/4885HTR1A 1354/4885
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS HTR7 1419/4885HTR6 1131/4885HTR1A 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.